Evolving Treatment Landscape in Myelodysplastic Syndromes - Episode 2

Risk Stratification of Myelodysplastic Syndromes

January 30, 2024

Andrew Brunner, MD, Amy DeZern, MD, MHS, Ehab L. Atallah, MD, Yasmin Abaza, MD

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Diagnosis of Myelodysplastic Syndromes (MDS)

Now Viewing

EP. 2: Risk Stratification of Myelodysplastic Syndromes

EP. 3: First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

EP. 4: Patient Profile 1: A 72-Year-Old Man With MDS

EP. 5: Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia

EP. 6: Patient Profile 2: A 77-Year-Old Man With MDS

EP. 7: Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia

EP. 8: ESA Treatment Selection in MDS

EP. 9: Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS

EP. 10: Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

EP. 11: IMerge: Imetelstat in Patients With Lower-Risk MDS

EP. 12: Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

EP. 13: Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

EP. 14: Treatment Options and Unmet Needs in Higher-Risk MDS

EP. 15: Updates from ASH 2023 in Higher-Risk MDS

EP. 16: Takeaways from ASH 2023 in Higher-Risk MDS

EP. 17: Closing Thoughts on the MDS Treatment Landscape